Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
(53 intermediate revisions by 3 users not shown)
Line 5: Line 5:
  
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
 
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
 +
 +
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]]
 +
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]]
 
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 Dec-2014]]
 +
  
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
Line 14: Line 18:
 
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]]  
 
*[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]]  
  
−
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.02.11.docx|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-02-11]]
+
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean.pdf|QIBA CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening]] ''2018.11.18''
  
 
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]]
 
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]]
Line 20: Line 24:
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
  
−
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]]  
+
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
  
−
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]]
 
−
 
−
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
 
  
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
  
−
Submit comments using the online form: ''' http://tinyurl.com/QIBA-Public-Comment-Form '''
+
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']'''
−
<br \><font size="2" color="FireBrick">(Note: each form accommodates 10 comments; submit additional forms as necessary)</font>
+
 
 +
*[[Media:QIBADWIProfile_as_of_2019-Feb-05.pdf|Diffusion-Weighted Magnetic Resonance Imaging Profile 2019-02-05]] ('''closed''' on EOB April 5th)
  
−
* ''There are currently no Profiles open for Public Comment''
+
*[[Media:QIBA_CTA_Profile_as_of_2019-Feb-29.pdf| Atherosclerosis Biomarkers by (C)CTA - 2019 Imaging Profile 2019-02-26]] (open for public comment until EOB June 3rd)
  
  
−
Public Comment '''closed''' for the following Profiles (comment resolution is underway on the corresponding committee page):
+
'''[[Comment Resolutions]]''' are posted for '''Past Public Comments''' and '''Past Technical Confirmations''' .
−
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI 2017-06-19]] (''Closed on December 31, 2017'')
 
−
*[[Media:QIBA_PET Amyloid_Profile_15June2017-post-public-comment.pdf | PET Amyloid: 18F-labeled PET Tracers Targeting Amyloid as an Imaging Biomarker - 2018-05-02]] (''Closed on September 15, 2017'')
 
−
*[[Media:Draft-MRE-QIBAProfile-2017-07-28_clean.pdf| MR Elastography 2017-08-15]] (''Closed on September 15, 2017'')
 
−
*[[Media:QIBADWIProfilev1.45_20170427_v5_accepted_linenumbers.pdf| MR DWI 2017-04-27]] (''Closed on August 25, 2017'')
 
  
  

Revision as of 19:06, 14 May 2019

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles


Stage 2: Consensus Profiles


Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations .


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL

Example:

QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles

Statements of Endorsement


See Also

Retrieved from "https://qibawiki.rsna.org/index.php?title=Profiles&oldid=14067"